Cited by 426Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsGenetic factors in colorectal cancer

The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

Open access

Cremolini, Chiara, Rossini, Daniele, Dell’Aquila, Emanuela, Lonardi, Sara, Conca, Elena, Del Re, Marzia, Busico, Adele, Pietrantonio, Filippo, Danesi, Romano, Aprile, Giuseppe, Tamburini, Emiliano, Barone, Carlo, Masi, Gianluca, Pantano, Francesco, Pucci, Francesca, Corsi, Domenico C., Pella, Nicoletta, Bergamo, Francesca, Rofi, Eleonora, Barbara, Cecilia, Falcone, Alfredo, Santini, Daniele·2019·JAMA Oncology

DOI 10.1001/jamaoncol.2018.5080PMC PMC6439839

Open this paper in CoChat — free account Open PDF

Abstract

Importance: Based on a small retrospective study, rechallenge with cetuximab-based therapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC) who were previously treated with the same anti-epidermal growth factor receptor-based regimen might be efficacious. Recent data suggest the role of liquid biopsy as a tool to track molecular events in circulating tumor DNA (ctDNA). Objective: To prospectively assess the activity of cetuximab plus irinotecan as third-line treatment for patients with RAS and BRAF wild-type mCRC who were initially sensitive to and then resistant to first-line irinotecan- and cetuximab-based therapy. Design, Setting, and Participants: Multicenter phase 2 single-arm trial conducted from January 7, 2015, to June 19, 2017. Liquid biopsies for analysis of ctDNA were collected at baseline. Main eligibility criteria included RAS and BRAF wild-type status on tissue samples; prior first-line irinotecan- and cetuximab-based regimen with at least partial response, progression-free survival of at least 6 months with first-line therapy, and progression within 4 weeks after last dose of cetuximab; and prior second-line oxaliplatin- and bevacizumab-based treatment. Interventions: Biweekly cetuximab, 500 mg/m2, plus irinotecan, 180 mg/m2. Main Outcomes and Measures: Overall response rate according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary end points included progression-free survival and overall survival and, as an exploratory analysis, RAS mutations in ctDNA. Results: Twenty-eight patients (9 women and 19 men; median age, 69 years [range, 45-79 years]) were enrolled. Six partial responses (4 confirmed) and 9 disease stabilizations were reported (response rate, 21%; 95% CI, 10%-40%; disease control rate, 54%; 95% CI, 36%-70%). Primary end point was met because lower limit of 95% CI of response rate was higher than 5%. RAS mutations were found in ctDNA collected at rechallenge baseline in 12 of 25 evaluable patients (48%). No RAS mutations were detected in samples from patients who achieved confirmed partial response. Patients with RAS wild-type ctDNA had significantly longer progression-free survival than those with RAS mutated ctDNA (median progression-free survival, 4.0 vs 1.9 months; hazard ratio, 0.44; 95% CI, 0.18-0.98; P = .03). Conclusions and Relevance: This is the first prospective demonstration that a rechallenge strategy with cetuximab and irinotecan may be active in patients with RAS and BRAF wild-type mCRC with acquired resistance to first-line irinotecan- and cetuximab-based therapy. The evaluation of RAS mutational status on ctDNA might be helpful in selecting candidate patients. Trial Registration: ClinicalTrials.gov Identifier: NCT02296203.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2018.5080

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
(2013) · JAMA · doi:10.1001/jama.2013.281053 · Cited by 30,732
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,825
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citation
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915 · cited 1×
“Objective response ratea (95% CI) 6 (21) (10-40)”
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Self-citation
Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Self-citation
Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Self-citation
COSMIC: somatic cancer genetics at high-resolution
Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C. G., Ward, S., Dawson, E., Ponting, L., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1121 · Cited by 1,922

Show all 38 references

Research works printed but not linked: 3

Meazza, 2016, AKT1 and BRAF mutations in pediatric aggressive fibromatosis., Cancer Med, 5, 1204, 10.1002/cam4.2016.5.issue-6 · DOI
dbSNP: short genetic variations. Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine. https://www.ncbi.nlm.nih.gov/SNP/. Accessed June 15, 2018.
ClinVar. https://www.ncbi.nlm.nih.gov/clinvar/. Accessed June 15, 2018.

Sorted by citations

Items 201–300 of 426

Targeting the MAP Kinase Pathway in Colorectal Cancer: A Journey in Personalized Medicine
Appleyard, J. W., Williams, C. J. M., Manca, P., Pietrantonio, F., & Seligmann, J. F. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0107 · Cited by 10
Self-citation
Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
Ciardiello, D., Famiglietti, V., Napolitano, S., Esposito, L., Normanno, N., Avallone, A., Latiano, T. P., Maiello, E., Pietrantonio, F., Cremolini, C., et al. (2021) · Cancers · doi:10.3390/cancers13225715 · Cited by 11
Self-citation
Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?
Vasconcelos, J. P. S., Boutin, M., & Loree, J. M. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221143975 · Cited by 11
SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)
Montés, A. F., Alonso, V., Aranda, E., Élez, E., Alfonso, P., Grávalos, C., Maurel, J., Vera, R., Vidal, R., & Aparicio, J. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03199-1 · Cited by 12
A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial
Izawa, N., Masuishi, T., Takahashi, N., Shoji, H., Yamamoto, Y., Matsumoto, T., Sugiyama, K., Kajiwara, T., Kawakami, K., Aomatsu, N., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00963-9 · Cited by 12
Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
Taniguchi, H., Yamanaka, T., Sakai, D., Muro, K., Yamazaki, K., Nakata, S., Kimura, H., Ruff, P., Kim, T. W., Peeters, M., et al. (2020) · Cancers · doi:10.3390/cancers12071715 · Cited by 10
Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
Epistolio, S., Cefalì, M., Spina, P., Molinari, F., Movilia, A., Cergnul, M., Mazzucchelli, L., Dosso, S. D., Frattini, M., & Saletti, P. (2021) · Oncotarget · doi:10.18632/oncotarget.27965 · Cited by 10
The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study
Tsai, H., Lin, C., Sung, Y.-C., Chen, S., Chen, L., Jiang, J., & Wang, J. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02366-z · Cited by 9
Circulating tumor DNA in colorectal cancer: biology, methods and applications
Chen, H., An, Y., Wang, C., & Zhou, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-02220-z · Cited by 10
Patient-derived organoids (PDOs) as a promising platform for personalized treatment of colorectal cancer: current applications and future challenges
Liu, Y., Zhang, Y., Zhang, R., Zhang, C., & Liu, X. (2025) · Cancer Biology & Therapy · doi:10.1080/15384047.2025.2567802 · Cited by 11
Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer
Dazio, G., Epistolio, S., Frattini, M., & Saletti, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247523 · Cited by 10
Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer
Bai, M., Lu, Y., Shi, C., Yang, J., Li, W., Yin, X., Huang, C., Shen, L., Xie, L., & Ba, Y. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0301 · Cited by 10
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study
Raimondi, A., Corallo, S., Lonardi, S., Antoniotti, C., Rimassa, L., Amatu, A., Tampellini, M., Racca, P., Murialdo, R., Clavarezza, M., et al. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-020-05972-2 · Cited by 9
Self-citation
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
Fucà, G., Raimondi, A., Prisciandaro, M., Lonardi, S., Cremolini, C., Ratti, M., Clavarezza, M., Murialdo, R., Bianchi, A. S., Smiroldo, V., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab012 · Cited by 9
Self-citation
Embracing Project Optimus: Can we Leverage Evolutionary Theory to Optimize Dosing in Oncology?
Qi, T., Dunlap, T. C., & Cao, Y. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03380-1 · Cited by 9
A systematic review of salvage therapies in refractory metastatic colorectal cancer
Petrelli, F., Perego, G., Ghidini, A., Ghidini, M., Borgonovo, K., Scolari, C., Nozza, R., Rampulla, V., Costanzo, A., Varricchio, A., et al. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03571-5 · Cited by 11
Self-citation
Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer
Internò, V., Tucci, M., Pezzicoli, G., Silvestris, F., Porta, C., & Mannavola, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581130 · Cited by 9
Plasma VEGF-A Short Isoforms as a Predictive Biomarker for Bevacizumab Efficacy in First-Line Treatment of Metastatic Colorectal Cancer: A Phase II Study (WJOG7612GTR)
Ismail, S. F., Hassan, N. A., & Musa, M. H. (2025) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/pciagz3vsm · Cited by 8
Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective “Real-World Study”
Coutzac, C., Trouilloud, I., Artru, P., Henriques, J., Masson, T., Doat, S., Bouché, O., Coriat, R., Saint, A., Moulin, V., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.12.003 · Cited by 8
Circulating tumor DNA: A new tool to predict recurrence and guide treatment of colorectal cancer
Quang, E. V., Gandini, A., Taly, V., Laurent‐Puig, P., Zaanan, A., & Taı̈eb, J. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102611 · Cited by 9
Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey
Basile, D., Gallois, C., Puglisi, F., Cohen, R., Goèré, D., Aprile, G., Lepage, C., Laurent‐Puig, P., Maïo, M. D., Lecomte, T., et al. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101681 · Cited by 8
Self-citation
Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis
Parisi, A., Ghidini, M., Giampieri, R., Tomasello, G., Luciani, A., Ferri, C., Berardi, R., & Petrelli, F. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.12.005 · Cited by 8
KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR
Pinheiro, M., Peixoto, A., Rocha, P., Veiga, I., Pinto, C., Santos, C., Pinto, P., Guerra, J., Escudeiro, C., Barbosa, A. P. F., et al. (2022) · International Journal of Colorectal Disease · doi:10.1007/s00384-022-04126-6 · Cited by 8
Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial
Pietrantonio, F., Fucà, G., Manca, P., Pagani, F., Raimondi, A., Prisciandaro, M., Randon, G., Corti, F., de Braud, F., Cremolini, C., et al. (2020) · Tumori Journal · doi:10.1177/0300891620960808 · Cited by 8
Self-citation
Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer
Wang, W., Huang, Y., Kong, J., Lü, L., Liao, Q., Zhu, J., Wang, T., Yan, L., Dai, M., Chen, Z., et al. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03422-7 · Cited by 7
What Is Next for Refractory Colorectal Cancer CRC? Looking Beyond SUNLIGHT, FRESCO2, RECURSE and CORRECT
Cherri, S., Libertini, M., Noventa, S., Oneda, E., Meriggi, F. A., & Zaniboni, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062522 · Cited by 8
RNF114 facilitates the proliferation, stemness, and metastasis of colorectal cancer
Liu, S., Gong, L., Huang, F.-C., Xu, N., Yang, K., Liu, X., & Li, W. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154716 · Cited by 7
Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer
Bonilla, C., Montenegro, P., O’Connor, J. M., Hernando, O., Aranda, E., Pinto-Llerena, J., Llontop, A., Escobar, J. G., Romero, M. D. C. D., Bautista-Hernández, Y., et al. (2023) · Cancers · doi:10.3390/cancers15174373 · Cited by 8
Clinical application of circulating tumor DNA in metastatic cancers
Raei, N., Safaralizadeh, R., & Latifi‐Navid, S. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2268008 · Cited by 8
Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients
Lavacchi, D., Gelmini, S., Calabri, A., Rossi, G., Simi, L., Caliman, E., Mancini, I., Salvianti, F., Petroni, G., Guidolin, A., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21853 · Cited by 7
MiR-135b-5p promotes cetuximab resistance in colorectal cancer by regulating FOXN3
Peng, C., Li, X., Yao, Y., Nie, Y., Fan, L., & Zhu, C. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2373497 · Cited by 7
Information technology competency and supply chain performance: role of risk management orientation and supply chain agility
Rasool, M., Murtza, M. H., Rasheed, M. I., Leong, A. M. W., Okumuş, F., & Bai, J. (2024) · Journal of Hospitality and Tourism Technology · doi:10.1108/jhtt-08-2023-0240 · Cited by 10
Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma
Komatsu, S., Yano, Y., Kido, M., Kuramitsu, K., Gon, H., FUKUSHIMA, K., Urade, T., So, S., Yanagimoto, H., Toyama, H., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15268 · Cited by 7
A segmentation-based sequence residual attention model for KRAS gene mutation status prediction in colorectal cancer
Zhao, L. F., Song, K., Ma, Y., Cai, M., Qiang, Y., Sun, J., & Zhao, J. (2022) · Applied Intelligence · doi:10.1007/s10489-022-04011-3 · Cited by 7
CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice
D'Onofrio, R., Caputo, F., Prampolini, F., Spallanzani, A., Gelsomino, F., Bettelli, S. R., Manfredini, S., Bonetti, L. R., Carotenuto, P., Bocconi, A., et al. (2022) · Tumori Journal · doi:10.1177/03008916221122554 · Cited by 7
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial
Germani, M. M., Vetere, G., Giordano, M., Ciracì, P., Capone, I., Tamborini, E., Conca, E., Busico, A., Pietrantonio, F., Piva, V. M., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1307545 · Cited by 7
Self-citation
Perspectives for circulating tumor DNA in clinical management of colorectal cancer
Takemasa, I., Hamabe, A., & Ishii, M. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01937-5 · Cited by 7
Liquid biopsy in colorectal cancer: No longer young, but not yet old
Roviello, G., Lavacchi, D., Antonuzzo, L., Catalano, M., & Mini, E. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i15.1503 · Cited by 7
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study
Signorelli, C., Calegari, M. A., Anghelone, A., Passardi, A., Frassineti, G. L., Bittoni, A., Lucchetti, J., Angotti, L., Giacomo, E. D., Zurlo, I. V., et al. (2024) · Current Oncology · doi:10.3390/curroncol31120574 · Cited by 6
Self-citation
ALKBH5 suppresses m6A mRNA modification of FOXM1 to drive Cetuximab resistance in KRAS-mutant colorectal cancer
Han, H., Li, Y., Lin, Z., Ma, X., Huang, W., Lu, C., Ma, R., & Han, R. (2025) · Oncogene · doi:10.1038/s41388-025-03490-1 · Cited by 6
Prognostic Significance of the Comprehensive Biomarker Analysis in Colorectal Cancer
Potievskaya, V. I., Tyukanova, E. S., Sekacheva, M. I., Fashafsha, Z. Z. A., Fatyanova, A. S., Potievskiy, M. B., Kononova, E., Kholstinina, A., Polishchuk, E., Shegai, P., et al. (2025) · Life · doi:10.3390/life15071100 · Cited by 7
Smaller, cheaper, faster: where next for liquid biopsies?
Gristina, V., Pepe, F., Ogliari, F. R., Russo, T. D. B., Gottardo, A., Russo, G., Incorvaia, L., Guerry, J. A., Pisapia, P., Scimone, C., et al. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2534961 · Cited by 7
Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study
Martelli, V., Vidal, J., Gibert, J., Fernández‐Rodríguez, C., Linares, J., Alfonso, P. G., Páez, D., Alonso, V., Gómez‐España, A., Guix, M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105760 · Cited by 7
Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling
Martini, G., Napolitano, S., Ciardiello, D., Bielo, L. B., Martinelli, E., Troiani, T., Zampino, M. G., Fazio, N., Curigliano, G., & Ciardiello, F. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01126-1 · Cited by 6
Liquid biopsy for KRAS, NRAS and BRAF mutation testing in advanced colorectal cancer patients: the Argentinean experience
Güttlein, L. N., Luca, M. R., Esteso, F., Fresno, C., Mariani, J. A., Pizarro, M. O., Brest, E., Starapoli, S., Kreimberg, K., Teves, P., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0329 · Cited by 6
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy
Gonzalez, N. S., Marchese, P. V., Baraibar, I., Ros, J., Salvà, F., Rodrı́guez, M., Salvà, C., Vaghi, C., Alcaráz, A., García, A., et al. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2349287 · Cited by 6
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report
Lastraioli, E., Lavacchi, D., Palmieri, V. E., Castiglione, F., Messerini, L., Costanzo, F. D., & Antonuzzo, L. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000923 · Cited by 6
Noninvasive Evaluation of EGFR Expression of Digestive Tumors Using 99m Tc-MAG 3 -Cet-F(ab′) 2 -Based SPECT/CT Imaging
Shi, D., Zhang, Y., Xu, Z., Si, Z., Cheng, Y., Cheng, D., & Liu, G. (2022) · Molecular Imaging · doi:10.1155/2022/3748315 · Cited by 6
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives
Alfonso, P. G., Valladares‐Ayerbes, M., Martín, A. J. M., Herrero, R. M., Muñoz, E. G., & Prat-Llorens, G. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2477192 · Cited by 5
CACA guidelines for holistic integrative management of rectal cancer
Wang, G., Fan, D., Gu, J. F., Ding, K., Fang, X., Shen, L., Xu, Z., Xu, J., Cai, J., Cai, L., et al. (2023) · Holistic Integrative Oncology · doi:10.1007/s44178-023-00023-2 · Cited by 5
Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer
Sagawa, T., Sato, Y., Hirakawa, M., Hamaguchi, K., Tamura, F., Nagashima, H., Fujikawa, K., Okamoto, K., Kawano, Y., Sogabe, M., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1203296 · Cited by 5
Focus on RAS Codon 61 Mutations in Metastatic Colorectal Cancer: A Retrospective Analysis
Schietroma, F., Anghelone, A., Valente, G., Beccia, V., Caira, G., Spring, A., Trovato, G., Bello, A. D., Ceccarelli, A., Chiofalo, L., et al. (2024) · Cancers · doi:10.3390/cancers16050988 · Cited by 5
Early Detection, Precision Treatment, Recurrence Monitoring: Liquid Biopsy Transforms Colorectal Cancer Therapy
Raval, H., & Bhattacharya, S. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096295070240318075023 · Cited by 5
Exploring RAS mutation incidence and temporal heterogeneity in metastatic colorectal cancer patients – a single-institution experience utilising circulating tumour DNA
Zarkavelis, G., Amylidi, A.-L., Torounidou, N., Yerolatsite, M., Keravasili, A., Keramisanou, V., & Mauri, D. (2024) · Współczesna Onkologia · doi:10.5114/wo.2024.138899 · Cited by 6
Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries
Shouki, B., Abdelsalam, A., Abdullah, A. S., Alshammari, K. M., Ahmed, A. M., Dawoud, E., Heinemann, V., Mohamed, A., Chehal, A. A., Mohammed, A., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241299324 · Cited by 5
Analysis of Efficacy, Safety, and Prognostic Factors of mFOLFOX6 Regimen Combined with Cetuximab and Simvastatin in the Treatment of K-RAS Mutant Colorectal Cancer
Li, G., & Liu, J. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/2280440 · Cited by 5
Retracted
Line by Line: Distinct Patterns of Anti-EGFR Antibody Resistance by Line of Therapy
Corcoran, R. B. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01922 · Cited by 5
Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis
He, Y., Wu, L., Qi, X., Wang, X., He, B., Zhang, W., Zhao, W., Deng, M., Xiong, X., Wang, Y., et al. (2024) · Integrative Cancer Therapies · doi:10.1177/15347354241242110 · Cited by 5
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways
Pastò, B., Buzzatti, G., Schettino, C., Malapelle, U., Bergamini, A., Angelis, C. D., Musacchio, L., Dieci, M. V., Kuhn, E., Lambertini, M., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104379 · Cited by 5
Chemotherapy Rechallenge or Reintroduction Compared to Regorafenib or Trifluridine/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A Propensity Score Analysis of Treatment Beyond Second Line (Proserpyna Study)
Calegari, M. A., Zurlo, I. V., Dell’Aquila, E., Basso, M., Orlandi, A., Bensi, M., Camarda, F., Anghelone, A., Pozzo, C., Sperduti, I., et al. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.06.002 · Cited by 6
Self-citation
Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?
Muscolino, P., Scimone, C., Sapuppo, E., Micali, V., Vasta, I., Santacaterina, A., Santarpía, M., & Russo, A. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.06.003 · Cited by 5
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial
Martinelli, E., Ciardiello, D., Martini, G., Napolitano, S., Tufo, S. D., D’Ambrosio, L., Chiara, M. D., Famiglietti, V., Nacca, V., Cardone, C., et al. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01372-0 · Cited by 5
Self-citation
Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies
Wang, L., Cao, H., Jiang, C., He, W., You, Y., Peng, K., Jin, Y., & Xia, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.587692 · Cited by 5
Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
Chennamadhavuni, A., & Kasi, P. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.847299 · Cited by 5
The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer
Kourié, H. R., Ibnshamsah, F., Zouein, J., Naim, N., Abbasi, S., Allahloubi, N. M. A., Al-Naqqash, M. A., Alolayan, A. A. M., Alshehri, A., Bitar, N., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0282 · Cited by 5
Validation of the Labcorp Plasma Focus Test to Facilitate Precision Oncology Through Cell-Free DNA Genomic Profiling of Solid Tumors
Verner, E. L., Jackson, J., Severson, E. A., Valkenburg, K. C., Greer, A. E., Riley, D. R. J., Sausen, M., Maddox, C., McGregor, P. M., Karandikar, A., et al. (2023) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2023.03.008 · Cited by 5
Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019
Lau, D. K., Burge, M., Roy, A. C., Chau, I., Haller, D. G., Shapiro, J. D., Peeters, M., Pavlakis, N., Karapetis, C. S., Tebbutt, N. C., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1744439 · Cited by 5
EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance
Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073265 · Cited by 4
Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study
Fukuda, K., Osumi, H., Yoshinami, Y., Ooki, A., Takashima, A., Wakatsuki, T., Hirano, H., Nakayama, I., Ouchi, K., Sawada, R., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05893-1 · Cited by 5
Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer
Gao, Z., Wang, X., Song, T., Shen, Z., Wang, X., Wu, S., & Jin, X. S. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i29.109947 · Cited by 4
Current status and perspectives of genetic testing in gastrointestinal cancer (Review)
Matsuoka, T., & Yashiro, M. (2023) · Oncology Letters · doi:10.3892/ol.2023.14155 · Cited by 5
Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy
van Dijk, E. J., Nienhuis, H. H., van den Eertwegh, A. J. M., Boers‐Sonderen, M. J., Bloem, M., Kamphuis, A. M., Ros, M. M., Bos, C., Aarts, M. J. B., van den Berkmortel, F. W. P. J., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03027-z · Cited by 4
Impact of the tumor immune contexture in microsatellite-stable metastatic colorectal cancer treated with avelumab, cetuximab, and irinotecan
Huyghe, N. D., Benidovskaya, E., Masoodi, T., Sinapi, I., Cuyper, A. D., Vempalli, F. R., Beyaert, S. P., Bouzin, C., Osorio, F. M., Ferraro, L., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102201 · Cited by 4
The impact of RAS mutation on the treatment strategy of colorectal cancer
Pirvu, E. E., Severin, E. M., Niţă, I., & Toma, Ş. A. (2023) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2408 · Cited by 4
Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients
Salvatore, L., Bensi, M., Vivolo, R., Zurlo, I. V., Dell’Aquila, E., Grande, R., Anghelone, A., Emiliani, A., Citarella, F., Calegari, M. A., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1125013 · Cited by 4
Self-citation
Multimodal Treatment of Metastatic Rectal Cancer in a Young Patient: Case Report and Literature Review
Popescu, I., Dudau, A.-M., Dima, S., Herlea, V., Croitoru, V. M., Dinu, I. M., Miron, M. I., Lupescu, I. G., Cazacu, I. M., Dumitru, R. L., et al. (2024) · Medicina · doi:10.3390/medicina60050696 · Cited by 5
Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer
D’Angelo, F., Monnien, F., Overs, A., Pem, I., Dor, F., Abad, M., Felix, S. A., Selmani, Z., Lakkis, Z., Borg, C., et al. (2024) · Diagnostic Pathology · doi:10.1186/s13000-024-01508-y · Cited by 4
First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?
Airoldi, M., Bartolini, M., Fazio, R., Farinatti, S., Daprà, V., Santoro, A., & Puccini, A. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01601-x · Cited by 5
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial
Stahler, A., Karthaus, M., Fruehauf, S., Graeven, U., Müller, L., von Weikersthal, L. F., Caca, K., Goekkurt, E., Ballhausen, A., Sommerhäuser, G., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.103004 · Cited by 4
Liquid Biopsy and Colorectal Cancer
Aggarwal, S., Chougle, A., Talwar, V., Shukla, P., Rohtagi, N., Verma, A., Pasricha, R. K., Sirohi, B., Agarwal, C., Pasricha, S., et al. (2024) · South Asian Journal of Cancer · doi:10.1055/s-0044-1801753 · Cited by 7
Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study
Signorelli, C., Calegari, M. A., Anghelone, A., Passardi, A., Gallio, C., Bittoni, A., Lucchetti, J., Angotti, L., Giacomo, E. D., Zurlo, I. V., et al. (2025) · Cancers · doi:10.3390/cancers17122037 · Cited by 4
Self-citation
Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia
Price, T. J., Burge, M., Chantrill, L. A., Gibbs, P., Pavlakis, N., Shapiro, J. D., & Sjoquist, K. M. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13336 · Cited by 5
Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
Ikeda, A., Aoki, K., Kawamura, M., Yamaguchi, D., & Kokuryu, H. (2021) · Internal Medicine · doi:10.2169/internalmedicine.5552-20 · Cited by 4
Exploring Better Strategies for RAS Mutation-Associated EGFR-Targeted Resistance in Colorectal Cancer: From the Perspective of Cancer Community Ecology
Wang, X., Wu, W., Zheng, Z., & Chi, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.754220 · Cited by 5
Systemic treatment for metastatic colorectal cancer
Leowattana, W., Leowattana, P., & Leowattana, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i10.1425 · Cited by 5
Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis
Xue, W.-H., Li, X., Ding, Y.-Q., Wu, N., Pei, B., Ma, X.-Y., Xie, J., & Yang, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1165040 · Cited by 3
Evaluation of the Prognostic Value of Low-Frequency KRAS Mutation Detection in Circulating Tumor DNA of Patients with Metastatic Colorectal Cancer
Lin, C., Shen, M., Chen, W. T., & Yang, C. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13071051 · Cited by 4
The Importance of Feasibility Assessment in the Design of ctDNA Guided Trials – Results From the OPTIPAL II Study
Callesen, L. B., Boysen, A. K., Andersen, C. S. A., Pallisgaard, N., & Spindler, K. G. (2023) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2023.07.005 · Cited by 4
Temporal dynamics of RAS mutations in circulating tumor DNA in metastatic colorectal cancer: clinical significance of mutation loss during treatment
Iguchi, K., Shiozawa, M., UCHIYAMA, M., Asari, M., Numata, K., Rino, Y., & Saito, A. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05805-3 · Cited by 3
Anti-EGFR Rechallenge in Metastatic Colorectal Cancer and the Role of ctDNA: A Systematic Review and Meta-analysis
da Silva, L. F. L., Saldanha, E. F., da Conceição, L. D., Noronha, M. M., Silva, M. V., & Peixoto, R. D. (2024) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01152-1 · Cited by 3
Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping
Sgouros, J., Eliades, A., Papadopoulou, K., Korfiatis, N., Papamichael, D., Fountzilas, E., Tsolaki, E., Achilleos, A., Tsangaras, K., Loizides, C., et al. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100120 · Cited by 3
Multiplexed tumor-mimetic dECM-chip platform for colorectal cancer: Interrogating pharmacological synergy and NK cell immunosurveillance dynamics
Li, Y., Wang, J., & Liang, L. (2025) · Talanta · doi:10.1016/j.talanta.2025.129012 · Cited by 4
Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib
Kawczak, P., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062387 · Cited by 4
Liquid Biopsy in Colorectal Cancer: Future Perspectives Through the Lens of Artificial Intelligence—A Comprehensive Review of Novel Literature
Păduraru, D. N., Palcău, A. C., Gorecki, G.-P., Dinulescu, A., & Băean, M.-L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093951 · Cited by 3
Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer
Liu, X., Ma, X., Ou, K., Wang, Q., Gao, L., & Yang, L. (2023) · Cancer Management and Research · doi:10.2147/cmar.s398539 · Cited by 3
Liquid Biopsy in Advanced Colorectal Cancer: Clinical Applications of Different Analytes
Delcuratolo, M. D., Modrego-Sánchez, A., Bungaro, M., Antón-Pascual, B., Terán, S., Dipace, V., Novello, S., García‐Carbonero, R., Passiglia, F., & Graválos-Castro, C. (2023) · Journal of Molecular Pathology · doi:10.3390/jmp4030013 · Cited by 3
Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment
Zhou, Y., Zhao, X., Lu, N., Cao, P., Leng, W.-B., Zhu, Q., Gou, H., Zhang, J., Li, X., & Qiu, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111887 · Cited by 3
Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer
Zhou, Y., Wu, S., & Qu, F.-J. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i6.2362 · Cited by 3
Efficacy and safety of trifluridine/tipiracil plus bevacizumab across different subgroups of patients with refractory colorectal cancer: a meta-analysis
Silva, L. F. L., Saldanha, E. F., da Conceição, L. D., Martins, W. D. A., Gismondi, R. A., Filho, E. M. D. S., & Peixoto, R. D. (2024) · ecancermedicalscience · doi:10.3332/ecancer.2024.1728 · Cited by 3
Prognostic Relevance of ctDNA RAS Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab
Kim, S., Lee, J. S., Kim, J. E., Kim, J. E., Hong, Y. S., & Kim, T.-W. (2025) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2025.03.002 · Cited by 3

Circulating tumor DNA to guide rechallenge with cetuximab plus irinotecan in Chinese RAS/BRAF wild type metastatic colorectal cancer: A phase II trial.
Li, Y.-H., De-shen, W., Chen, W., Ren, C., Wang, F., Wang, Z., Luo, H., Wang, F., & Tan, Q. (2026) · Journal of Clinical Oncology · doi:10.1200/jco.2026.44.2_suppl.154
Abstract CT088: Efficacy of anti-EGFR rechallenge in RAS and BRAF wt metastatic colorectal cancer: Clinical and translational results of the phase II CRICKET study by GONO
Rossini, D., Cremolini, C., Re, M. D., Lonardi, S., Busico, A., Rofi, E., Garattini, S. K., Tamburini, E., Dell’Aquila, E., Corsi, D. C., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-ct088 · Cited by 2
Self-citation
Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.
Rossini, D., Cremolini, C., Conca, E., Re, M. D., Busico, A., Pietrantonio, F., Bergamo, F., Danesi, R., Casagrande, M., Tamburini, E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.12007 · Cited by 16
Self-citation
Circulating tumour DNA to guide rechallenge with cetuximab plus irinotecan in RAS/BRAF wild‐type metastatic colorectal cancer: A nonrandomised clinical trial
Wang, D., Chen, W. C., Ren, C., Wang, F., Wang, Z., Luo, H., Wang, F., Tan, Q., & Li, Y. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70827
Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO
Rossini, D., Cremolini, C., Conca, E., Re, M. D., Busico, A., Pietrantonio, F., Bergamo, F., Danesi, R., Cardellino, G. G., Tamburini, E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy149.006 · Cited by 6
Self-citation

See all

Authors: Cremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., Tamburini, E., Barone, C., Masi, G., Pantano, F., Pucci, F., Corsi, D. C., Pella, N., Bergamo, F., Rofi, E., Barbara, C., Falcone, A., & Santini, D.
Affiliations: University of Pisa (IT)
Università Campus Bio-Medico (IT)
Istituto Oncologico Veneto (IT)
Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, Pisa, Italy
University of Udine (IT)
Ospedale Infermi di Rimini (IT)
Università Cattolica del Sacro Cuore (IT)
Ospedale di Parma (IT)
Fatebenefratelli Hospital (IT)
Medical Oncology Unit, Presidio Ospedaliero Felice Lotti, Pontedera, Italy
Corresponding author: Falcone, Alfredo
ORCID: Cremolini, Chiara
Rossini, Daniele
Dell’Aquila, Emanuela
Lonardi, Sara
Conca, Elena
Busico, Adele
Pietrantonio, Filippo
Danesi, Romano
Aprile, Giuseppe
Tamburini, Emiliano
Barone, Carlo
Masi, Gianluca
Pantano, Francesco
Corsi, Domenico C.
Bergamo, Francesca
Falcone, Alfredo
Santini, Daniele
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2019-03-01
Volume: 5
Issue: 3
Pages: 343
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2018.5080
PMC: PMC6439839
OpenAlex: W2901178367
Cited by: 424
References: 38
Citations by year: 2026: 36 · 2025: 48 · 2024: 75 · 2023: 66 · 2022: 72 · 2021: 61 · 2020: 47 · 2019: 18
FWCI: 11.91
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA Oncology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Funders: Amgen
Eli Lilly and Company
Sanofi
Celgene
F. Hoffmann-La Roche
Merck KGaA
Eisai
Università Cattolica del Sacro Cuore
Servier
Ipsen
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: metastatic colorectal cancer, cetuximab, irinotecan, drug rechallenge, RAS wild-type, BRAF wild-type, acquired resistance, anti-EGFR therapy, circulating tumor DNA, liquid biopsy, third-line therapy, oxaliplatin, bevacizumab, RAS mutations, progression-free survival, overall survival, response rate, disease control rate, predictive biomarkers
MeSH terms: Cetuximab, Irinotecan, Progression-Free Survival, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Italy, Male, Middle Aged, Prospective Studies, Genes, ras, Risk Factors, Time Factors, Biomarkers, Tumor, Colorectal Neoplasms, Disease Progression, Drug Resistance, Neoplasm, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks